Dermata Therapeutics Inc. has released a corporate presentation highlighting their advancements in dermatology treatments. The company showcases their unique, multi-use topical platform technology targeting the large medical and aesthetic dermatology market. Key developments include Xyngari, a once-weekly topical treatment for acne, which has shown statistically significant results in the STAR-1 Phase 3 study. A second Phase 3 study, STAR-2, is slated to begin in 2025. Additionally, Dermata's program for psoriasis has completed a positive Phase 1b study, and their DMT410 product for hyperhidrosis is planning a Phase 2a trial with DAXXIFY following a successful Phase 1 proof-of-concept with BOTOX. The presentation also outlines the market opportunities within dermatology, including a prevalence of 50 million acne cases in the US alone, and a growing demand for hyperhidrosis treatments. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。